Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA
Murphy L. et al, (2023), BLOOD, 142
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia.
Rastogi N. et al, (2022), Leukemia
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.
Coupe N. et al, (2022), Cell Oncol (Dordr)
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
HARRINGTON H. et al, (2022), Leukemia
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Taylor CA. et al, (2022), Nat Med
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Schnegg-Kaufmann AS. et al, (2022), Blood
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.
Ryou H. et al, (2022), Leukemia
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Moreno V. et al, (2022), Cancer Immunol Immunother, 71, 2985 - 2998
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G. et al, (2022), Blood Adv
Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies.
Khan AO. et al, (2022), Cancer Discov
Single-cell methods in myeloproliferative neoplasms - old questions, new technologies.
O'Sullivan JM. et al, (2022), Blood
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.
Zhang X-Y. and Collins GP., (2022), Curr Oncol Rep, 24, 1477 - 1488
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis EJ. et al, (2022), J Immunother Cancer, 10
HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).
Carlo-Stella C. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2
MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood.
Zavidij O. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S331 - S332
A qualitative exploration of digital medicines information usage: Insights from an evaluation of the BNF
Blagden S. et al, (2022), Health Policy and Technology, 11
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
Horgan D. et al, (2022), Healthcare (Basel), 10